Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 3/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | DUSP10 | Q9Y6W6 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TDP2 | O95551 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30724388 | 0.87 | CHRM2 (0.41) | HRH1CHRM2HTR1ACHRM1DRD2 | |
| SCHEMBL730635 | 0.83 | HRH1 (0.58) | HRH1CHRM2HTR1ACHRM1DRD2 | |
| SCHEMBL31317931 | 0.83 | HRH1 (0.58) | HRH1CHRM2HTR1ACHRM1DRD2 | |
| SCHEMBL9267882 | 0.82 | KMT2A (0.43) | HRH1CHRM2HTR1ACHRM1DRD2 | |
| SCHEMBL1864779 | 0.82 | CHRM2 (0.45) | HRH1CHRM2HTR1ACHRM1DRD2 | |
| SCHEMBL22579802 | 0.80 | TDP1 (0.42) | DUSP10MEN1KMT2ATDP2NSD2 | |
| SCHEMBL4095527 | 0.80 | HRH1 (0.49) | HRH1CHRM2HTR1ACHRM1DRD2 | |
| SCHEMBL17413659 | 0.78 | DRD2 (0.42) | HRH1CHRM2HTR1ACHRM1DRD2 | |
| SCHEMBL8348677 | 0.78 | — | — | |
| Bromide SCHEMBL8777272 | 0.76 | DRD2 (0.41) | HRH1CHRM2HTR1ACHRM1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111718381-A | Osmium metal organic compound containing polypyridine ligand and preparation method and application thereof | 荆楚理工学院 | 2020-09-29 | — | — | CN | claimed |
| EP-2072517-B1 | Asymmetric phenanthrolins, method for their manufacture and doped organic semiconductor material containing them | NOVALED GMBH (DE) | 2015-01-21 | — | — | EP | claimed |
| WO-2009083197-A2 | ASYMMETRIC PHENANTHROLINES, PREPARATION PROCESS THEREFORE AND DOPED ORGANIC SEMICONDUCTOR MATERIAL CONTAINING THEM | NOVALED AG (DE) | 2009-07-09 | — | — | WO | claimed |
| EP-2072517-A1 | Asymmetric phenanthrolins, method for their manufacture and doped organic semiconductor material containing them | Novaled AG (DE) | 2009-06-24 | — | — | EP | claimed |
| CN-116917271-A | Process for producing arylthiol ester compound | ＡＧＣ株式会社 | 2023-10-20 | — | — | CN | disclosed |
| EP-3239156-B1 | NOVEL GROUP 4 TRANSITION METAL COMPOUND AND USE OF SAME | HANWHA CHEMICAL CORP (KR) | 2023-03-01 | — | — | EP | disclosed |
| EP-3239157-B1 | NOVEL GROUP 4 TRANSITION METAL COMPOUND AND USE THEREOF | HANWHA CHEMICAL CORP (KR) | 2021-09-29 | — | — | EP | disclosed |
| CN-107001500-B | Novel group 4 transition metal compound and use thereof | 韩华化学株式会社 | 2020-11-03 | — | — | CN | disclosed |
| CN-107778309-B | Quinoline derivative and application thereof | 北京鼎材科技有限公司 | 2020-10-16 | — | — | CN | disclosed |
| CN-107001394-B | Novel group 4 transition metal compound and use thereof | 韩华化学株式会社 | 2020-03-20 | — | — | CN | disclosed |
| US-10377836-B2 | Group 4 transition metal compound and use thereof | HANWHA CHEMICAL CORPORATION (KR) | 2019-08-13 | — | — | US | disclosed |
| CN-105198793-B | Oxime ester photoinitiators | 巴斯夫欧洲公司 | 2019-08-13 | — | — | CN | disclosed |
| WO-2016105124-A1 | NOVEL GROUP 4 TRANSITION METAL COMPOUND AND USE THEREOF | 한화케미칼 주식회사 | 2016-06-30 | — | — | WO | disclosed |
| WO-2016105122-A1 | NOVEL GROUP 4 TRANSITION METAL COMPOUND AND USE OF SAME | 한화케미칼 주식회사 | 2016-06-30 | — | — | WO | disclosed |
| CN-104389159-A | Preparation method of polyphenylene sulfide chelate fiber | CHINA PETROLEUM & CHEMICAL | 2015-03-04 | — | — | CN | disclosed |
| EP-2072517-B1 | Asymmetric phenanthrolins, method for their manufacture and doped organic semiconductor material containing them | NOVALED GMBH (DE) | 2015-01-21 | — | — | EP | disclosed |
| CN-102633932-A | Characteristic fluorophore contained metal complex and application thereof | UNIV EAST CHINA SCIENCE & TECH | 2012-08-15 | — | — | CN | disclosed |
| CN-101849953-B | Inflammatory cytokine release inhibitor | INST MED MOLECULAR DESIGN INC | 2012-04-25 | — | — | CN | disclosed |
| WO-2009083197-A2 | ASYMMETRIC PHENANTHROLINES, PREPARATION PROCESS THEREFORE AND DOPED ORGANIC SEMICONDUCTOR MATERIAL CONTAINING THEM | NOVALED AG (DE) | 2009-07-09 | — | — | WO | disclosed |
| EP-2072517-A1 | Asymmetric phenanthrolins, method for their manufacture and doped organic semiconductor material containing them | Novaled AG (DE) | 2009-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377836-B2 | Group 4 transition metal compound and use thereof | TRPM4, MORF4L1, TRPV4 | HRH1 3611/4885CHRM2 3607/4885HTR1A 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.